A series of conjugates of 10-hydroxy camptothecin (HCPT) with functionalized norcantharidin derivatives were regioselectively synthesized in the condition of (3-dimethylaminopropyl) ethyl-carbodiimide monohydrochloride in a moderate yield. The synthesized conjugate HCPT pro-drugs can also suppress cancer cell growth in vitro. These conjugated pro-drug constructs possess therapeutic potential as novel bi-functional conjugate platforms for cancer treatment.
Introduction
Topoisomerase I, a vital DNA-manipulating enzyme, is the only known target for camptothecin [1] [2] [3] , which binds to the interface of the covalent protein-nucleic acid complex. 20-(S)-Camptothecin (CPT) was discovered in the early 1960s, by Wani's group at the NCI, from an extract of the bark of the Chinese tree Camptotheca acuminata-a common deciduous tree used for ages in traditional Chinese medicine. Owing to the high toxicity and low bioavailability, camptothecin was not usable as an anticancer agent in vivo [4, 5] .
It was discovered that the quinoline moiety of CPT could be substituted without loss of activity. This bicyclic moiety can be modified with a large amount of functional groups [6] , especially the introduction of hydroxyl group in 10- while preserving and even in some cases promoting the cytotoxic action of the parent natural product. Structure reactivity relationship studies of camptothecin derivatives summarized that a hydroxyl substitution at the 10-position, such as topotecan and irinotecan, enhanced antitumour activity [7] . This led to the design and development of the two major anticancer drugs topotecan and irinotecan [8] (figure 1).
In general, for a given cancer there are several operating cancer genes or pathways. At the same time, metastasis is a major obstacle to anticancer therapies and responsible for most therapeutic failures, while drug resistance is always going to be a concern. Given these things, the dual target drug will be needed for optimal therapeutic effect [9] [10] [11] [12] [13] .
In our ongoing project, 10-hydroxy camptothecin (HCPT) was chosen as a main anticancer pro-drug to conjugate with another anticancer drug norcantharidin owing to its unique feature of stimulation of the bone marrow production of white cells, which is in contrast to most other anticancer drugs that readily induce myelo-suppression [14] [15] [16] . The dual anticancer drug assemblies [17, 18] were thus constructed, because HCPT is a DNA-topoisomerase I inhibitor and norcantharidin will also suppress cancer cell growth by inhibiting protein phosphatase.
With the encouragement of irinotecan and other similar derivatives, we supposed that a conjugate of HCPT with norcantharidin in 10-phenolic ester may improve its efficiency (figure 2). The research result is summarized in the following.
Material and methods
1 H NMR spectra were recorded at 400 MHz on a Varian Unity INOVA 400 MHz NMR spectrometer using tetramethylsilane as an internal standard, and 13 
Proliferation inhibition assay
The inhibition ratio using the HCPT conjugate 3 was evaluated with standard 3-(4, 11.010.510.0 9.5 9.0 8. A series of conjugated camptothecin norcantharidin 10-phenolic ester derivatives 3a-i were designed and synthesized regio-selectively in a moderate yield. As shown in table 1, most of the camptothecin norcantharidin 10-phenolic ester compounds have similar activities against HepG2, BGC803, SW480 and PANC-1 cell lines in vitro, and these compounds will be further tested against different cell lines in vivo.
Results and discussion
HCPT and norcantharidin are both commercially available materials, which were thus chosen as starting materials to prepare this target molecule (I) [19] . In our recent published literature [20] , a sealed tube
